Cellular Therapy Option for Treatment of Central Nervous System EBV-PTLD

Mar 20, 2019

Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.
 

Susan Prockop, MD, associate attending in pediatrics at Memorial Sloan Kettering Cancer Center, discusses an option available for the treatment of central nervous system (CNS) Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD).

According to a subset analysis, patients are at very high risk of developing this disease after hematopoietic stem cell transplant or solid organ transplant and the modalities available are still limited, Prockop says. A high dose of radiation can be debilitating with significant side effects, so adoptive immunotherapy with EBV-specific T cells is a good option for these patients.

Related Content